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SUCCESSFUL TREATMENT FOR RENAL CELL CARCINOMA 
WITH LUNG MET AST ASES BY INTERLEUKIN-2 
AND INTERFERON-ALFA: A CASE REPORT 
Yuko SAKATA， Yuji OGURA， Toshiaki WAKITA and Norio HAYASHI 
From the Department 01 Urology， Aichi Cancer Center 
Y oshiki SUGIMURA 
From the Dψartment 01 Urology， Mie University School 01 Medicine 
We report a case in which a regimen 0ぱfin則t臼E訂r巾lel引叩u北I品水出kinは (1比L-♂引2幻)and interferon alfi仏a(げIFN-α叫)was 
effective against renal cell carcinoma with lung metastases. A 69-year-old man diagnosed with right 
renal tumor had not received treatment for 28 months. He was admitted to our hospital for treatment. 
Computed tomographic (CT) findings showed a right renal tumor 11.5 cm in diameter and multiple 
lung metastases. Right nephrectomy was performed， and pathological examination was renal cell 
carcinoma (clear cell carcinoma， G2， pT3a). A regimen of IL-2 and IFN-a was selected as an 
adjuvant therapy. He received 70X 104 JRU/day ofIL-2 (div) 5 times a week， and 600X 104 IU/day 
ofIFN-αintramuscularly 3 times a week for 8 weeks. Thereafter， both treatments were continued 3 
times a week. CT scan showed a complete response on lung metastases 12 months and no recurrence 
has been observed on CT scan for 16 months after operation. 



















れていた. 1999年1月の CTで右腎腫蕩(径 4cm)
(Acta Urol. Jpn. 49: 389-391， 2003) 
を認め，右腎癌と診断，手術を勧められるも拒否して















病理組織所見:病理組織診断は， renal cel car-
cinoma， clear cel type， G2， INF-s， v (一)，腫蕩
は腎周囲脂肪織へ浸潤しており， pT3apNOM1， 
stage IVであった.
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Fig. 1. (a) Chest CT reveals lung metastases， 
left hilum， right upper and lower lobes 
before treatment (arrows). (b) Chest 
CT shows lung metastases are not 
observed 12 months after operation. 
術後経過(Fig.2) :術後経過は良好であり， 5月31











































右下肺野 1cm 司 NC =今軽度縮小=今
右肺野陰影癒痕化
=今消失
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Fig. 2. Clinical course. 
坂田，ほか腎癌肺転移 IL-2+IFN-α 併用療法 391 
よる免疫療法の効果は期待できないとしている. IL-





でも高い有効率が報告されており 8.10) 今後も IFN-
α単独投与を第一選択とするのがよいであろう.
近年.進行性腎細胞癌に対して IFN-α，IL-2など
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